These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 35179703)

  • 21. Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey.
    Allaire M; Manfredi S; Lerosey L; Ganne-Carrié N; Thabut D
    Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102059. PubMed ID: 36455860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
    Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Niizeki T; Montes M; Vivaldi C; Soldà C; Stefanini B; Hiraoka A; Sho T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Campani C; Amadeo E; Rossari F; Burgio V; Cascinu S; Scartozzi M; Casadei-Gardini A
    Eur J Cancer; 2023 Aug; 189():112933. PubMed ID: 37385069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma.
    Matsui T; Nagai H; Mukozu T; Wakui N; Matsuda T; Igarashi Y
    Clin J Gastroenterol; 2024 Aug; ():. PubMed ID: 39152332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of hepatocellular carcinoma with a portal vein tumor thrombus and pulmonary metastases of rectal cancer with microsatellite stability using atezolizumab plus bevacizumab.
    Inaba Y; Chatani S; Murata S; Sato Y; Imamine R; Kato M; Onaya H; Yamaura H
    Clin J Gastroenterol; 2024 Apr; 17(2):286-291. PubMed ID: 38341819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
    Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
    Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
    Song BG; Goh MJ; Kang W; Sinn DH; Gwak GY; Choi MS; Lee JH; Paik YH
    Gut Liver; 2024 Jul; 18(4):709-718. PubMed ID: 38932499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durable Stable Disease by Atezolizumab/Bevacizumab Can Provide Long-term Survival of Patients With Hepatocellular Carcinoma Lung Metastases.
    Motohara T; Yamamura K; Miyamoto H; Ueno S; Takeno H; Nagayama Y; Oda E; Karashima R; Ozaki N; Miyata T; Mima K; Okabe H; Isiko T; Beppu T
    In Vivo; 2023; 37(5):2268-2275. PubMed ID: 37652506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
    Ben Khaled N; Seidensticker M; Ricke J; Mayerle J; Oehrle B; Rössler D; Teupser D; Ehmer U; Bitzer M; Waldschmidt D; Fuchs M; Reuken PA; Lange CM; Wege H; Kandulski A; Dechêne A; Venerito M; Berres ML; Luedde T; Kubisch I; Reiter FP; De Toni EN
    Future Oncol; 2022 Apr; 18(12):1423-1435. PubMed ID: 35081747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.
    Ai H; Gong T; Ma Y; Ma G; Ding W; Ding W; Wang W; Zhao X
    Front Immunol; 2024; 15():1358602. PubMed ID: 38863699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
    Kudo M; Aoki T; Ueshima K; Tsuchiya K; Morita M; Chishina H; Takita M; Hagiwara S; Minami Y; Ida H; Nishida N; Ogawa C; Tomonari T; Nakamura N; Kuroda H; Takebe A; Takeyama Y; Hidaka M; Eguchi S; Chan SL; Kurosaki M; Izumi N
    Liver Cancer; 2023 Sep; 12(4):321-338. PubMed ID: 37901197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
    Chen YH; Chen YY; Wang JH; Hung CH
    Anticancer Res; 2023 Mar; 43(3):1377-1384. PubMed ID: 36854513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A Case of Successful Treatment of Recurrent Peritoneal Dissemination of Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Combination Therapy].
    Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Shinke G; Katsuyama S; Ikeshima R; Kawai K; Hiraki M; Sugimura K; Masuzawa T; Takeno A; Hata T; Murata K
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):2027-2029. PubMed ID: 35045482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study.
    Ishikawa T; Yamazaki S; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Anticancer Res; 2024 Jan; 44(1):361-368. PubMed ID: 38159993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk.
    Kurisaki K; Soyama A; Hara T; Matsushima H; Imamura H; Tanaka T; Adachi T; Ito S; Kanetaka K; Hidaka M; Okano S; Eguchi S
    Dig Surg; 2023; 40(1-2):84-89. PubMed ID: 36848877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Shimose S; Iwamoto H; Shirono T; Tanaka M; Niizeki T; Kajiwara M; Itano S; Yano Y; Matsugaki S; Moriyama E; Noda Y; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Cancer Med; 2023 Jun; 12(11):12325-12335. PubMed ID: 37062077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
    Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
    Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
    Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
    Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Salani F; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Schirripa M; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Scartozzi M; Cascinu S; Casadei-Gardini A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7565-7577. PubMed ID: 36976353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.